Adagrasib alone, with cetuximab shows ‘encouraging’ activity in advanced colorectal cancer
Adagrasib alone and in combination with cetuximab exhibited promising efficacy compared with historical outcomes among heavily pretreated patients with advanced colorectal cancer who had KRASG12C mutations.The agent — both alone and as part of combination therapy — also exhibited a favorable safety profile, according to researchers who presented results of the phase 1/phase 2 KRYSTAL-1 study at ESMO Congress.An estimated 3% to 4% of people with colorectal cancer harbor KRASG12C mutations, and patients with these alterations typically do not survive as long after standardRead More
